Scopri i 4 Corsi precongressuali in programma ad ICAR 2024 che...
Scopri i 4 Corsi precongressuali in programma ad ICAR 2024 che si svolgeranno in contemporanea mercoledì 19 giugno dalle ore 15.00 alle ore 17.30.
I 4 Corsi Precongressuali ICAR 2024 si svolgeranno in contemporanea mercoledì 19 giugno dalle ore 15.00 alle ore 17.30.
Accedi a MyICAR e registrati gratuitamente ai corsi, riceverai conferma dell'avvenuta iscrizione da parte del Provider.
Immune response in viral infections: where we are with new knowledge
Chairs: E. Cimini (Roma), S. Piconi (Lecco)
In the host, innate and adaptive immunity are the arms of a functional and well-organized immune response against several pathogens. Beside immune system, inflammation protects the host by eliminating pathogens, repairing damaged tissue, and restoring homeostasis. Inflammasome is the core component of the inflammatory response, having a crucial role in resisting pathogenic infections and maintaining immune homeostasis by releasing inflammatory soluble factors. An overactive inflammasome can also trigger a cytokine storm, leading to various inflammatory diseases and exacerbating tissue damage. During viral infections, a balanced immune/inflammatory response is prominent in resolving the infection. Innate immunity implements non cellular/cellular strategies to eliminate viruses in the early stage of infection, by priming specific T and B cells responses in the resolving phase. Viruses are able to modify host’s immune response both in acute/chronic phases of infection, by evolving mechanisms to evade or to yperactivate immune response by damaging the host. T cells have a pivotal role in controlling infectious diseases and cancer. Chimeric antigen receptor T-cells (CAR-T) therapy has emerged as a highly efficacious treatment modality for refractory and relapsed hematopoietic malignancies in recent years. Thus, it seems likely that engineered, re-directed T cells will also be able to control these diseases when naturally occurring T cells fail. A successful effector CAR-T cell therapy is designed to kill every cancer or virus-infected cell in the patient. By understanding the biology of naturally occurring T cells, these advances will help the field to engineer better T cells to function in a wide array of disease areas. In this pre-congress course we will deepen the innovative diagnostic and therapeutic aspects in the control of acute and chronic viral infections in view of the clinical and pathogenetic relevance of the host’s immune response during viral infections.
Innate immunity and inflammation R. Rovito, Milano
Adaptive immune response in viral infections: T and B lymphocytes S. De Biasi, Modena
Monoclonal antibodies in viral infections E. Andreano, Siena
Novel T-cell therapies in viral infections V. Bordoni, Roma
Addressing viral persistence today and tomorrow
Chairs: C. Alteri (Milano), C. Scagnolari (Roma)
The last decade has seen a profound change in our understanding of viral persistence as a much more dynamic picture of the reservoir emerged. The mechanisms that prevent HIV and HBV eradication have been redefined, as well as their role in chronic immune activation and inflammation. At the same time, the COVID-19 global pandemic caused by the SARS-CoV-2 reopens questions about the ability of some RNA viruses to drive chronic symptoms by persisting in certain body sites or tissue reservoirs after acute infection. In summary, viral persistence is undoubtedly complex and multifaceted process, but if approached from the right angle, can yield many clues for the identification of new weapons and new curative strategies to counteract it. Thus, this course is shedding light on the state of the art as well as the most recent discoveries and fascinating innovations in HIV, HBV, HDV persistence and post-COVID-19 syndrome. It uncovers putative links between viral persistence, viral evolution, host immune status, and protective immunity to guide and direct future basic science and clinical research priorities.
HIV-1: markers for persistence, latency and resistance
The virological point of view O. Turriziani, Roma
The clinical point of view M. Iannetta, Roma
HBV/HDV: from virology to pathophysiology
The virological point of view R. Salpini, Roma
The clinical point of view E. Degasperi, Milano
SARS-CoV-2: evolution and monitoring
The virological point of view A. Pierangeli, Roma
The clinical point of view A. Lombardi, Milano
Complexities of HIV management: when the going gets tough... the tough get going!
Chairs: F. Bai (Milano), C. Pinnetti (Roma)
The aim of this pre-congressional course is to reflect on some topics in the management of HIV infection of high clinical complexity. The simultaneous presence of multiple comorbidities can create extreme difficulties for clinicians in the daily clinical management of the person living with HIV. The course is aimed at young infectivologists who will be able to interactively discuss with tutors the approach of five different HIV-related issues. The course aims to critically analyse diagnostic and therapeutic choices in order to synthesise practical management principles useful in clinical practice.
Saturday Naive Fever: when two (or more) infections are better than one A. Mondi, Roma
Atypical mycobacteriosis yes or not: that is the question A. Giacomelli, Milano
End-stage liver disease in HIV: when and how to get ready for transplant? M. Merli, Milano
Empathetic Care in Action: Navigating the Complex Journey of Transgender Individuals Living with HIV G. Lapadula, Monza
What ulcer can I do for you? N. Girometti, London UK
Ageing in people with HIV: a feasible challenge
Chairs: G. Giupponi (Como), F. Leserri (Roma), N. Squillace (Monza)
Ageing is a physiologic process consisting of physical and mental changes. It is primarily influenced by a genetic factors but also by various external factors including diet, exercise, stress, and smoking. HIV infection has been associated with early ageing. Frailty is a clinically state increased vulnerability, resulting from age-associated declines in physiologic reserve and function across multiple organ systems, such that the ability to cope with everyday or acute stressors is compromised. Frailty is strictly associated with ageing and quality of life. Peoples living with HIV (PWH) are at increased risk of myocardial infarction: a recent trial has confirmed a beneficial impact of statin therapy also in PWH older than 40 yo with a low cardiovascular risk. Other comorbidities such as diabetes, hypertension and depression contribute to polypharmacy in PWH. The aim of the course is to analyze the principle issues regarding Ageing in PWH and how to manage them focusing on practical recommendations.
Results of a Survey about Quality of Life in persons with HIV N. Policek, Edimburg UK
What is frailty and how can we prevent and manage it? J. Milic, Modena
Less is more: how can we manage polypharmacy in persons with HIV? M. Ferrara, Torino
If I feel sad, what should I do? Depression burden in persons with HIV M.G. Strepparava, Milano
INMI, Istituto Nazionale per le Malattie Infettive
ISS, Istituto Superiore di Sanità
AMCLI, Associazione Microbiologi Clinici Italiani
SIICA, Società Italiana di Immunologia, Immunologia Clinica e Allergologia
SIMaST, Società Interdisciplinare per lo Studio delle Malattie Sessualmente Trasmissibili
SITA, Società italiana per la Terapia Antinfettiva Antibatterica Antivirale Antifungina
SIV-ISV, Società Italiana di Virologia - Italian Society for Virology
ANLAIDS, Associazione Nazionale per la lotta all'AIDS
ARCIGAY, Arcigay Associazione LGBTQIA+ Italiana
ARCOBALENO Aids ODV, Associazione ARCOBALENO Aids ODV
ASA, Associazione Solidarietà AIDS-ODV
C.I.C.A., Coordinamento Italiano delle case alloggio per persone con HIV/AIDS
EpaC Onlus, Associazione EpaC Onlus
LILA, Lega Italiana per la lotta contro l'AIDS
MARIO MIELI, Circolo di Cultura Omosessuale
Milano Check Point, Associazione Milano Check Point